The researchers conducted this study as previous ones have not assessed death rate variations among patients with chronic obstructive pulmonary disease (COPD) across the urban-rural gradient.
All-cause mortality is disproportionately higher in patients with chronic obstructive pulmonary disease (COPD) living in urban areas and lower-income neighborhoods, according to a study published in International Journal of Chronic Obstructive Pulmonary Disease.
The researchers emphasized that most COPD studies focus on individual patient risk factors and that fewer are population based and include community risk factors.
“Identifying both individual and community risk factors associated with higher mortality in people with COPD is essential to improve outcomes,” the authors wrote.
Consequently, the researchers identified neighborhood socioeconomic status and urbanicity as possible factors associated with differences in disease severity and related mortality. They noted that “the variation in death rates among patients with COPD has not been assessed across the urban-rural gradient.” They also explained that few studies examining community risk factors within COPD mortality include race.
“To address this gap in knowledge, we used geographically precise patient-level data from a large cohort of patients with COPD to describe the associations between demographic characteristics and socioeconomic status with all-cause mortality,” the authors wrote.
The study population consisted of all patients enrolled in the Veteran Health Administration (VHA) with at least 1 International Classification of Diseases, Ninth Revision or 10th Revision codes for COPD between 2016 and 2019. The researchers obtained demographic characteristics, comorbidities, and geocoded residential addresses; they used the addresses to classify each patient’s Area Deprivation Index and rurality before assessing the association between these characteristics and age-adjusted all-cause mortality.
Using their criteria, the researchers identified over 1 million patients with COPD, 33.4% of whom had died as of January 2021. The study population consisted of a male patient majority (95.5%), and the White (78.3%) and Black (13.2%) patient populations resembled the racial breakdowns observed in the general US population. Also, most of the cohort lived in urban areas (58.8%), and 39.5% and 1.6% lived in rural and highly rural areas, respectively.
Through age-adjusted models, the investigators found an association of all-cause mortality with Black race (odds ratio [OR], 1.09; 95% CI, 1.08-1.11) and higher neighborhood disadvantages (OR, 1.30; 95% CI, 1.28-1.32). After adjusting for all covariates, including comorbidities, gender, and socioeconomic status, the association between all-cause mortality and Black patients with COPD reversed, and these patients had a reduced risk of death (aOR, 0.98; 95% CI, 0.96-0.99). The researchers noted that this implies that race alone does not determine all-cause mortality and that other factors influence it.
They also associated lower odds of all-cause mortality with female sex (OR, 0.67; 95% CI, 0.65-0.69), Asian race (OR, 0.64; 95% CI, 0.59-0.70), and living in a highly rural area (aOR, 0.92; 95% CI, 0.89-0.95).
Overall, the researchers found that all-cause mortality in patients with COPD is disproportionately higher among individuals living in lower-income neighborhoods and urban areas, “suggesting the impact of social determinants of health on COPD outcomes.”
Despite their findings, the researchers identified several limitations to their study, one being that their population was predominately male. Since they created their population based on those receiving care in the VHA, they explained that the cohort is biased toward male patients, limiting the capacity to make conclusions about the female patient population.
Because of the discrepancies in their findings in terms of race, the researchers concluded by explaining that future research should “focus on exploring mechanisms by which disparities arise and developing interventions to address these,” namely in Black patients with COPD.
Reference
Robichaux C, Aron J, Wendt CH, et al. Sociodemographic and geographic risk factors for all-cause mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2023;18:1587-1593. doi:10.2147/COPD.S406899
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More